Related Experiment Video
Updated: Jun 17, 2026
05:17
Intravenous Injections in Neonatal Mice
Published on: November 11, 2014
Does IVIg administration yield improved immune function in very premature neonates?
J L Wynn1, P C Seed, C M Cotten
1Division of Neonatology, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA. james.wynn@duke.edu
Summary
Intravenous immunoglobulin (IVIg) shows limited success for neonatal sepsis due to immature immune systems in premature infants. Research is needed to understand IVIg
Area of Science:
- Neonatal immunology
- Immunotherapy
- Premature infant health
Background:
- Neonatal sepsis is a significant concern, particularly in very premature infants.
- Intravenous immunoglobulin (IVIg) has been explored as a treatment for neonatal sepsis.
- Clinical success of IVIg has been modest, possibly due to immature neonatal immune systems.
Purpose of the Study:
- To review evidence on IVIg effects on immune function in very premature neonates (<30 weeks gestational age).
- To understand how IVIg impacts the developing immune system in this vulnerable population.
- To identify future research directions for optimizing IVIg therapy in very premature infants.
Main Methods:
- Literature review of studies investigating IVIg in very premature neonates.
- Analysis of immune function markers following IVIg administration.
- Synthesis of existing data on IVIg's immunoenhancing potential.
Main Results:
- Evidence suggests IVIg can modulate immune responses in very premature neonates.
- Specific effects of IVIg on immature immune cells require further detailed investigation.
- The biological plausibility for IVIg's benefit is high, but clinical outcomes need improvement.
Conclusions:
- Understanding IVIg's impact on immature immune systems is crucial for very premature neonates.
- Targeted research is necessary to enhance IVIg efficacy in preventing or treating neonatal sepsis.
- Optimizing IVIg therapy could improve outcomes for the most vulnerable infants.
Related Concept Videos
01:22Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:15Transcytosis of IgG
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...